I'd like to hear Wayne articulate a detailed path to cashflow positive.
I appreciate that he explained that part of issuing the options during the last raise was for the potential cash injection it could give down the track.
Will cash burn stay at circa $40mil per annum? Is it likely to rise/fall?
I recall back in the 'Code Red' days he referred to changing the culture around expenses (including mini bar charges etc), I'm keen to better understand the staff and admin costs and if there is a plan to reduce these in the future or will they rise as a result of the EFS trial?
Could, for example, the Early Feasibility Study be conducted on 2,000 rather than 1,000 patients?
(2,000 x $25k) = $50mil USD less (say) 25% for cost of goods -> $37.5mil divided by 0.7 USD -> AUD = $53mil AUD = breakeven? (what have I missed / incorrectly assumed?)
AVR Price at posting:
$23.49 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)